To overcome these hurdles, researchers are exploring next-generation ADC designs incorporating novel payloads, modified antibody backbones and new drug linker-release mechanisms.
The pharma will acquire Araris Biotech to gain access to three preclinical ADCs and a linking technology Araris claims is superior to existing platforms.
The FDA thinks an antibody-drug conjugate (ADC) developed by AbbVie could set new standards in treatment for certain patients with lung cancer, awarding the drug breakthrough status. Teliso-V ...
Expression data from patient-derived xenograft (PDX) mouse models exposed to micvotabart pelidotin (MICVO) indicate gene signatures associated ...
Q4 2024 Earnings Call Transcript March 27, 2025 ADC Therapeutics SA beats earnings expectations. Reported EPS is $-0.29, ...
Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback